Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "poultry" return 94 results.
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines
Ceva will be at the 18th World’s Poultry Congress >
Congress Center, Nantes Events Center «La Cité»
Ceva’s growth continues despite difficult market conditions >
Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. C...
Signature of a scientific collaboration protocol about avian influenza with South China Agricultural University >
Paris, May 29th 2013 1- Ceva, a socially responsible company committed to the well-being of the planet Ceva Santé Animale is a multi-national French based animal health company that counts over 3000 e...
New Technology Vaccine Symposium - Miami >
Ceva shares global field experiences through New Technology Vaccine Symposium held in the US. Innovation in the hatchery will drive productivity gains
Hatchery vaccination services >
The best vaccines can only work if they are administered properly, inside the bird or the egg, in the right place, at the right dose and in a clean environment.
Ceva records double digit growth for 3rd. successive year >
14% growth pushes sales beyond 600 M€ for first time
Ceva presents a complete range of vector vaccines at IPE 2013 >
Vectormune® ND and Transmune® IBD, “The Perfect Pair” of vaccines for Gumboro and Newcastle prevention can now be administered in one injection at the hatchery.
Ceva announces scientific breakthrough with the launch of Vectormune® AI >
Vectormune® AI a new generation vaccine for the control of Avian Influenza.
AXA Private Equity provides additional financing to support the development of Ceva >
AXA Private Equity, the leading European diversified private equity firm, announces today that it is providing €100 million of additional financing to support the development of Ceva.